{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:32:18Z","timestamp":1775871138000,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1136\/ijgc-2022-003880","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T05:50:25Z","timestamp":1700545825000},"page":"586-593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct01293630","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01293630","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-0247","authenticated-orcid":false,"given":"Koji","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Sunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Ecstein-Fraisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7388-0243","authenticated-orcid":false,"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003880_bb0010","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/cncr.24975","article-title":"Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer","volume":"116","author":"McKeage","year":"2010","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003880_bb0015","doi-asserted-by":"crossref","first-page":"173692","DOI":"10.1016\/j.ejphar.2020.173692","article-title":"Vascular disrupting agents in cancer therapy","volume":"891","author":"Smolarczyk","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1136\/ijgc-2022-003880_bb0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2017.01.031","article-title":"The development and use of vascular targeted therapy in ovarian cancer","volume":"145","author":"Chase","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003880_bb0025","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/sj.bjc.6601261","article-title":"Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis","volume":"89","author":"Hori","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003880_bb0030","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1158\/0008-5472.CAN-06-4018","article-title":"Antitumor and antivascular effects of AVE8062 in ovarian carcinoma","volume":"67","author":"Kim","year":"2007","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2022-003880_bb0035","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1349-7006.1999.tb00724.x","article-title":"Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy","volume":"90","author":"Nihei","year":"1999","journal-title":"Jpn J Cancer Res"},{"key":"10.1136\/ijgc-2022-003880_bb0040","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.1999.tb00850.x","article-title":"A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors","volume":"90","author":"Nihei","year":"1999","journal-title":"Jpn J Cancer Res"},{"key":"10.1136\/ijgc-2022-003880_bb0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/RLI.0b013e3181577cfc","article-title":"Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography","volume":"43","author":"Lavisse","year":"2008","journal-title":"Invest Radiol"},{"key":"10.1136\/ijgc-2022-003880_bb0050","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2613.2009.00651.x","article-title":"Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies","volume":"90","author":"Kanthou","year":"2009","journal-title":"Int J Exp Pathol"},{"key":"10.1136\/ijgc-2022-003880_bb0055","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1634\/theoncologist.2010-0432","article-title":"Cardiovascular toxicity profiles of vascular-disrupting agents","volume":"16","author":"Subbiah","year":"2011","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2022-003880_bb0060","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s10637-014-0119-0","article-title":"Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin\/docetaxel or carboplatin\/paclitaxel in patients with advanced solid tumors","volume":"32","author":"Bahleda","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1136\/ijgc-2022-003880_bb0065","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1349-7006.2003.tb01419.x","article-title":"Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo","volume":"94","author":"Morinaga","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1136\/ijgc-2022-003880_bb0070","unstructured":"Ministry of Health, Labour and Welfare . ICH E6 (R1) guideline for good clinical practice. Available: https:\/\/www.pmda.go.jp\/files\/000156725.pdf [Accessed 2 Jun 2022]."},{"key":"10.1136\/ijgc-2022-003880_bb0075","doi-asserted-by":"crossref","unstructured":"World Medical Association . Declaration of Helsinki: ethical principles for medical research involving human subjects - last amended by the 59th WMA General Assembly, Seoul 2008. Available: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/ [Accessed 2 Jun 2021].","DOI":"10.1515\/9783110208856.233"},{"key":"10.1136\/ijgc-2022-003880_bb0080","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jjco\/hyy026","article-title":"Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors","volume":"48","author":"Nishio","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003880_bb0085","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(15)70102-6","article-title":"Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Blay","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003880_bb0090","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ygyno.2020.01.005","article-title":"Pazopanib and fosbretabulin in recurrent ovarian cancer (PAZOFOS): a multi-centre, phase 1B and open-label, randomised phase 2 trial","volume":"156","author":"Morgan","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003880_bb0095","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2015.65.8153","article-title":"Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"34","author":"Monk","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003880_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/biostatistics\/2.2.203","article-title":"Statistical properties of the traditional algorithm\u2010based designs for phase I cancer clinical trials","volume":"2","author":"Lin","year":"2001","journal-title":"Biostatistics"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:19:20Z","timestamp":1744507160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24013409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1048891X24013409"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003880","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}